Brad Spellberg

Corporate Officer/Principal at University of California, Los Angeles

Health Technology

Consumer Services

Profile

Brad Spellberg is currently a Professor at the University of California, Los Angeles.
He previously worked as Vice President-Research at NovaDigm Therapeutics, Inc.

Brad Spellberg active positions

Companies	Position	Start
University of California, Los Angeles	Corporate Officer/Principal	-

All active positions of Brad Spellberg

Former positions of Brad Spellberg

Companies	Position	End
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Chief Tech/Sci/R&D Officer	-

See the detail of Brad Spellberg's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Brad Spellberg's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Health Technology